Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Olszewski AJ, et al. Among authors: grossbard ml. J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2. J Gastrointest Cancer. 2013. PMID: 23208490 Clinical Trial.
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P. Araneo M, et al. Among authors: grossbard ml. Cancer Invest. 2003;21(4):489-96. doi: 10.1081/cnv-120022357. Cancer Invest. 2003. PMID: 14533437 Clinical Trial.
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P. Rachamalla R, et al. Among authors: grossbard ml. Anticancer Drugs. 2004 Mar;15(3):211-7. doi: 10.1097/00001813-200403000-00004. Anticancer Drugs. 2004. PMID: 15014353 Clinical Trial.
The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ, Grossbard ML, Kozuch PS. Olszewski AJ, et al. Among authors: grossbard ml. Oncology (Williston Park). 2005 Mar;19(3):297-306; discussion 306, 308, 317-33. Oncology (Williston Park). 2005. PMID: 15828549 Free article. Review.
Metastatic pancreatic cancer 2008: is the glass less empty?
Nieto J, Grossbard ML, Kozuch P. Nieto J, et al. Among authors: grossbard ml. Oncologist. 2008 May;13(5):562-76. doi: 10.1634/theoncologist.2007-0181. Oncologist. 2008. PMID: 18515741 Free article. Review.
Empowering targeted therapy: lessons from rituximab.
Olszewski AJ, Grossbard ML. Olszewski AJ, et al. Among authors: grossbard ml. Sci STKE. 2004 Jul 6;2004(241):pe30. doi: 10.1126/stke.2412004pe30. Sci STKE. 2004. PMID: 15252219 Review.
103 results